🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

HIV post-treatment controllers have distinct immunological and virological features

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2218960120Source: DataRank Database

HIV post-treatment controllers have distinct immunological and virological features is a research paper published in Proceedings of the National Academy of Sciences (2023). On theSindex it has a DataRank of 0.628. It has been cited 65 times.

N/A

0.628DataRank · unranked

Scored on demand from live citation data

Open Access65 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (36 grants)Impact (FWCI 8.09)OA: greenTopics (60)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.628

From this paper's citation signal

Citation Network Contribution

0

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (28)

Xiaoming Sun ORCID,Yijia Li ORCID,Meghan Melberg,Daniela Moïsi ORCID,Rachel Gottlieb

Live enrichment

PubMed:36877848 OpenAlex:https://openalex.org/W4323306381

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: AI068634

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: AI068636

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: AI106701

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: AI150396

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: AI164560

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: P30 AI045008

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: UM1 AI069534

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: AI069412

Ruth L. Kirschstein National Research Service Award (NRSA)

Grant: 5T32AI007387-32

Multidisciplinary AIDS Training Program

HHS | NIH | NIAID | Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases

Grant: P30 AI060354

Frederick National Laboratory for Cancer Research

Grant: HHSN261200800001E

National Institutes of Health

Grant: 3UM1AI106701-12S1

AIDS Clinical Trial Group Laboratory Center

National Institutes of Health

Grant: 5UM1AI069534-19

University of Pennsylvania HIV Clinical Trials Unit

National Institutes of Health

Grant: 5U01AI068636-03

AIDS Clinical Trials Group Network

National Institutes of Health

Grant: 5P30AI045008-10

Core--Immunology Facility

National Institutes of Health

Grant: 1R01AI150396-01

HIV Reservoir Ecology of Viral Remission

National Institutes of Health

Grant: 1P30AI060354-01

Harvard Medical School Center for AIDS Research

National Institutes of Health

Grant: 5P30AI060354-18

Harvard University Center for AIDS Research

National Institutes of Health

Grant: 5U01AI068634-03

Statistical and Data Management Center for the AIDS Clinical Trials Group

National Institutes of Health

Grant: 2UM1AI069412-08

Harvard/Boston/Providence Clinical Trials Unit (Harvard/B/P CTU)

National Institutes of Health

Grant: 5UM1AI164560-05

Delaney AIDS Research Enterprise to Cure HIV

NIAID NIH HHS

Grant: UM1 AI069501

NIAID NIH HHS

Grant: U01 AI069412

NIAID NIH HHS

Grant: UM1 AI164560

NIAID NIH HHS

Grant: U01 AI068636

CCR NIH HHS

Grant: HHSN261200800001C

NIAID NIH HHS

Grant: T32 AI007387

NIAID NIH HHS

Grant: UM1 AI069423

NIAID NIH HHS

Grant: UM1 AI069412

NIAID NIH HHS

Grant: UM1 AI068634

NIAID NIH HHS

Grant: R01 AI150396

NIAID NIH HHS

Grant: UM1 AI106701

NIAID NIH HHS

Grant: P01 AI169768

NIAID NIH HHS

Grant: P30 AI050410

NIAID NIH HHS

Grant: U01 AI068634

NIAID NIH HHS

Grant: UM1 AI068636

FWCI

8.09

Citation Percentile

1.0%

Citation Trend

2023

2024

2025

2026

greenLicense: cc-by-nc-nd

repositoryhttps://repository.arizona.edu/bitstream/10150/674610/1/etemad-et-al-2023-hiv-post-treatment-controllers-have-distinct-immunological-and-virological-features.pdf

repositoryhttps://repository.arizona.edu/bitstream/10150/674610/1/etemad-et-al-2023-hiv-post-treatment-controllers-have-distinct-immunological-and-virological-features.pdf

publisherhttps://pnas.org/doi/pdf/10.1073/pnas.2218960120

repositoryhttp://hdl.handle.net/10150/674610

journalhttps://doi.org/10.1073/pnas.2218960120

Fields of Study

HIV Research and TreatmentHIV-related health complications and treatmentsHIV/AIDS Research and Interventions03 medical and health sciences0303 health sciencesHumansCD8-Positive T-LymphocytesKiller Cells, NaturalLymphocyte ActivationRNAHIV InfectionsViremia

MeSH Terms

HumansKiller Cells, NaturalLymphocyte ActivationRNAViremiaHIV InfectionsCD8-Positive T-Lymphocytes

Keywords

ViremiaCD8ImmunologyT cellCellBiologyHuman leukocyte antigenViral loadCytotoxic T cellImmune systemHuman immunodeficiency virus (HIV)AntigenVirologyMedicineGeneticsIn vitroreservoir610HIV InfectionsCD8-Positive T-LymphocytesLymphocyte ActivationClinical Research616Medicine and Health Sciences2.1 Biological and endogenous factorsKiller CellsHumansBiomedical and Clinical SciencesHIVBiological SciencesKiller Cells, Naturalanalytical treatment interruptionInfectious DiseasesGood Health and Well Beingpost-treatment controllerMedical MicrobiologyNaturalHIV/AIDSSexually Transmitted InfectionsRNAInfection

Sustainable Development Goals

SDG 0: Reduced inequalities

Related Papers (10)

Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies

Nature Communications(2025)

co-cited

10.1038/s41467-025-56116-1

Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1

Proceedings of the National Academy of Sciences(2020)

co-citedsame journal

10.1073/pnas.2020617117

Distinct viral reservoirs in individuals with spontaneous control of HIV-1

N/A

7.4DataRank · unranked

Nature(2020)

co-cited

10.1038/s41586-020-2651-8

Early Initiation of Antiretroviral Therapy Following In Utero HIV Infection Is Associated With Low Viral Reservoirs but Other Factors Determine Viral Rebound

The Journal of Infectious Diseases(2021)

co-cited

10.1093/infdis/jiab223

Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity

N/A

0.769DataRank · unranked

Nature Medicine(2020)

co-cited

10.1038/s41591-019-0747-1

Restriction of HIV-1 Escape by a Highly Broad and Potent Neutralizing Antibody

N/A

2.5DataRank · unranked

Cell(2020)

co-cited

10.1016/j.cell.2020.01.010

Continuous Prophylactic Antiretrovirals/Antiretroviral Therapy Since Birth Reduces Seeding and Persistence of the Viral Reservoir in Children Vertically Infected With Human Immunodeficiency Virus

Clinical Infectious Diseases(2020)

co-cited

10.1093/cid/ciaa718

The immune response fails to control HIV early in initial virus spread

Journal of Clinical Investigation(2020)

co-cited

10.1172/jci136886

Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021

N/A

0.889DataRank · unranked

Nature Medicine(2021)

co-cited

10.1038/s41591-021-01590-5

HIV-1 diversity considerations in the application of the Intact Proviral DNA Assay (IPDA)

N/A

3.4DataRank · unranked

Nature Communications(2021)

co-cited

10.1038/s41467-020-20442-3